Experienced in Primary Localized Cutaneous Amyloidosis

Dr. Barbara S. Civiello

Oncology | Hematology
Dana-Farber Cancer Institute, Inc.
101 Columbian St, 
South Weymouth, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Primary Localized Cutaneous Amyloidosis
Dana-Farber Cancer Institute, Inc.
101 Columbian St, 
South Weymouth, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Barbara Civiello is an Oncologist and a Hematologist in South Weymouth, Massachusetts. Dr. Civiello is rated as an Experienced provider by MediFind in the treatment of Primary Localized Cutaneous Amyloidosis. Her top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Breast Cancer.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NH
Hospital Affiliations
South Shore Hospital
Brigham And Women's Hospital
Wentworth-Douglass Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
101 Columbian St, South Weymouth, MA 02190

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
View 6 Less Clinical Trials

2 Total Publications

Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.
Journal: JCO oncology practice
Published: November 03, 2023
Similar Doctors
Distinguished in Primary Localized Cutaneous Amyloidosis
Dr. Raymond L. Comenzo
Hematology Oncology | Hematology
Distinguished in Primary Localized Cutaneous Amyloidosis
Dr. Raymond L. Comenzo
Hematology Oncology | Hematology

Pratt Medical Group Inc

800 Washigton St, 
Boston, MA 
 (13.2 miles away)
617-636-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raymond Comenzo is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Comenzo is rated as an Elite provider by MediFind in the treatment of Primary Localized Cutaneous Amyloidosis. His top areas of expertise are Primary Amyloidosis, Multiple Myeloma, Cardiac Amyloidosis, Bone Marrow Transplant, and Tissue Biopsy. Dr. Comenzo is currently accepting new patients.

Advanced in Primary Localized Cutaneous Amyloidosis
Dr. John M. Sloan
Hematology | Oncology
Advanced in Primary Localized Cutaneous Amyloidosis
Dr. John M. Sloan
Hematology | Oncology

Evans Medical Foundation Inc

1 Boston Medical Ctr Pl, 
Boston, MA 
 (12.5 miles away)
857-654-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Sloan is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Sloan is rated as a Distinguished provider by MediFind in the treatment of Primary Localized Cutaneous Amyloidosis. His top areas of expertise are Primary Amyloidosis, Lymphofollicular Hyperplasia, Adult T-Cell Leukemia, Colorectal Cancer, and Bone Marrow Transplant. Dr. Sloan is currently accepting new patients.

Vaishali H. Sanchorawala
Advanced in Primary Localized Cutaneous Amyloidosis
Dr. Vaishali H. Sanchorawala
Hematology | Oncology
Advanced in Primary Localized Cutaneous Amyloidosis
Dr. Vaishali H. Sanchorawala
Hematology | Oncology

Evans Medical Foundation Inc

88 E Newton St, 
Boston, MA 
 (12.6 miles away)
617-414-5405
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vaishali Sanchorawala is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Sanchorawala is rated as an Elite provider by MediFind in the treatment of Primary Localized Cutaneous Amyloidosis. Her top areas of expertise are Primary Amyloidosis, Cardiac Amyloidosis, Multiple Myeloma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Sanchorawala is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Civiello's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 25 Advanced Conditions
    View All 108 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile